en · de · es · fr · pt
sr9009-notes.peptides9000.com › Topic › Background And Mechanism Of Sr9009 — Worked Examples

Background And Mechanism Of Sr9009 — Worked Examples

By Editorial Desk · published 2025-09-24 · last reviewed 2025-11-04 · Topic

The short version of anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Related pages on this site

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Further detail

=== Production === Polystyrene is an addition polymer that results when styrene monomers polymerize (interconnect). This can be started by applying heat or benzoyl peroxide to styrene as initiators. As a liquid or a gas, pure styrene will polymerise spontaneously to polystyrene, without the need of external initiators. In the polymerization, the carbon–carbon π bond of the vinyl group is broken, and a new carbon–carbon σ bond is formed, attaching to the carbon of another styrene monomer to the chain. Since only one kind of monomer is used in its preparation, it is a homopolymer. The newly formed σ bond is stronger than the π bond that was broken, thus it is difficult to depolymerize polystyrene. About a few thousand monomers typically comprise a chain of polystyrene, giving a molar mass of 100,000–400,000 g/mol.

Instead, more diverse groups had greater viral diversity. Bats seem to be highly resistant to many of the pathogens they carry, suggesting a degree of adaptation to their immune systems. Their interactions with livestock and pets, including predation by vampire bats, compound the risk of zoonotic transmission. Bats have been connected to the emergence of severe acute respiratory syndrome (SARS) in China, since they serve as natural hosts for coronaviruses, several from a cave in Yunnan, one of which developed into the SARS virus. However, there is no evidence that bats cause or spread COVID-19.

They may have less vaginal atrophy and fewer problems concerning sexual intercourse. Vaginal changes that happen with aging and childbirth include mucosal redundancy, rounding of the posterior aspect of the vagina with shortening of the distance from the distal end of the anal canal to the vaginal opening, diastasis or disruption of the pubococcygeus muscles caused by poor repair of an episiotomy, and blebs that may protrude beyond the area of the vaginal opening. Other vaginal changes related to aging and childbirth are stress urinary incontinence, rectocele, and cystocele. Physical changes resulting from pregnancy, childbirth, and menopause often contribute to stress urinary incontinence. If a woman has weak pelvic floor muscle support and tissue damage from childbirth or pelvic surgery, a lack of estrogen can further weaken the pelvic muscles and contribute to stress urinary incontinence. Pelvic organ prolapse, such as a rectocele or cystocele, is characterized by the descent of pelvic organs from their normal positions to impinge upon the vagina. A reduction in estrogen does not cause rectocele, cystocele or uterine prolapse, but childbirth and weakness in pelvic support structures can. Prolapse may also occur when the pelvic floor becomes injured during a hysterectomy, gynecological cancer treatment, or heavy lifting. Pelvic floor exercises such as Kegel exercises can be used to strengthen the pelvic floor muscles, preventing or arresting the progression of prolapse.

== Applications in histology and pathology == Van Gieson’s stain is widely used to as a counterstain to evaluate connective tissue in both histology research and pathology. In medical liver biopsies, Hematoxylin–Van Gieson (HVG) stain is used to visualize the extent of fibrosis, as collagen appears bright pink/red. When used after Verhoeff’s elastic stain it reveals elastic fibers (stain black) and collagen (stain red). It differentiates between collagen and elastic fibers in tumor stroma. It is often used in general pathology to stain collagen and other connective tissues. as a quick “connective tissue” stain.

Sources: en.wikipedia.org

Supporting material

=== Pharmacokinetics === GBL is rapidly converted into GHB by paraoxonase (lactonase) enzymes, found in the blood. Animals which lack these enzymes exhibit no effect from GBL. GBL is more lipophilic (fat soluble) than GHB, and so is absorbed faster and has higher bioavailability. Because of these pharmacokinetic differences, GBL tends to be more potent and faster-acting than GHB, but has a shorter duration; whereas the related compound 1,4-butanediol (1,4-B) tends to be slightly less potent and slower to take effect but longer-acting than GHB.

== Aftermath == After returning to France in August 1804, Alexander von Humboldt and Aimé Bonpland arrived in Bordeaux after a swift Atlantic crossing. Their return after six years abroad was marked by the need to adjust to changed circumstances and reintegrate into European life. During quarantine, Humboldt wrote to the Institut National in Paris, informing them of his safe arrival. This news caused surprise, as rumors of his death had circulated in Europe. Humboldt reached Paris in late August, looking healthy and energetic. He was warmly welcomed by friends and family, with accounts noting he appeared unchanged by his long absence. Parisian society celebrated Humboldt as a hero. He was honored at scientific meetings and social gatherings, gaining widespread public attention for his South American explorations. His collections and drawings, exhibited at the Jardin des Plantes, attracted large crowds. Within six weeks, the Institut National held a special meeting where Humboldt presented his scientific results, receiving enthusiastic applause. In mid-October, Humboldt presented the first reports of his journey at a meeting of the Institut National des Sciences et Arts, a French government organisation created in 1795 to promote science, the beaux arts, and literature. The meeting was crowded and highly anticipated. In October of that year, the inaugural exhibition of Humboldt's botanical collection was inaugurated at the Jardin des Plantes, where it met with considerable acclaim.

Additional measures may include extracorporeal shockwave therapy or surgery. Between 4% and 7% of people have heel pain at any given time: about 80% are due to plantar fasciitis. Approximately 10% have the disorder at some point. It becomes more common with age. It is unclear whether one sex is more affected than the other.

Sources: en.wikipedia.org

Supporting material

== Cut anatomy and structure == The sirloin steak has several muscles that define the texture and flavor of different cuts. The sirloin does not do much work in supporting the cow, and so does not contain much reinforcing connective tissue. This makes the sirloin tender. The top sirloin primarily contains the Gluteus medius, along with the gluteus accessorius, gluteus profundus, and part of the biceps femoris. During butchery, these parts are separated along natural seams. These muscles differ in size and function. The gluteus medius is the largest and most prominent portion of the steak. These muscles contain connective tissue that contributes to differing tenderness between cuts. The gluteus medius cut is consistently tender. Heavily worked muscles, like the biceps femoris, are often firmer and more flavorful. The top sirloin cooks quicker than the bottom sirloin and is good for pan-searing and grilling. The bottom sirloin contains more muscles and is typically roasted or braised.

In the United Kingdom, a new excise duty on vaping products (Vaping Products Duty) is scheduled to take effect from 1 October 2026, with registrations opening on 1 April 2026, following consultation. The government said it would implement a flat-rate structure of £2.20 per 10 mL of vaping liquid, alongside a one-off increase in tobacco duty to preserve the financial incentive to switch from smoking to vaping.

In meteorites and in prebiotic experiments (e.g. Miller–Urey experiment) many more amino acids than the twenty standard amino acids are found, several of which are at higher concentrations than the standard ones. It has been conjectured that if amino acid based life were to arise elsewhere in the universe, no more than 75% of the amino acids would be in common. The most notable anomaly is the lack of aminobutyric acid.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network